Brief: Lantern Pharma Expands AI Capabilities Of RADR Platform To Accelerate Clinical Development Of Immune Checkpoint Inhibitors
28/08/2023 14:19
Aug 28 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA EXPANDS AI CAPABILITIES OF RADR® PLATFORM
TO
ACCELERATE THE CLINICAL DEVELOPMENT OF IMMUNE CHECKPOINT
INHIBITORS
Source text for Eikon: ID:nBw5CRnPGa
Further company coverage: LTRN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments